Avai BioAVAI +9.35%24 Earnings Yield (Joel Greenblatt) % is -1.91% as of Dec. 2025. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 2,902 Software companies, Avai Bio ranks worse than 74.12% on this metric.
Avai Bio's Enterprise Value for the quarter that ended in Dec. 2025 was $54.00 Mil.
Avai Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.03 Mil. Avai Bio's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was -1.91%.
The historical rank and industry rank for Avai Bio's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
AVAI'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9.73 Med: -0.98 Max: 0.22
Current: -4.13
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Avai Bio was 0.22%. The lowest was -9.73%. And the median was -0.98%.
AVAI's Earnings Yield (Joel Greenblatt) % is ranked worse than 74.12% of 2902
companies
in the Software industry
Industry Median: 1.955
vs AVAI: -4.13
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Avai Bio's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Avai Bio (OTCPK:AVAI) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Avai Bio Earnings Yield (Joel Greenblatt) % Related Terms
Avai Bio Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Avai Bio's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Software - Application subindustry, Avai Bio's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avai Bio Earnings Yield (Joel Greenblatt) % vs Software Industry
For the Software industry and Technology sector, Avai Bio's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Avai Bio's Earnings Yield (Joel Greenblatt) % falls into.
Avai Bio Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Avai Bios Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2025 is calculated as
Avai Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.03 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -1.91% mean?
Avai Bio (AVAI) has a Earnings Yield (Joel Greenblatt) % of -1.91% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Avai Bio and its competitors. According to the industry distribution chart, Avai Bio ranks #2151 out of 2902 companies in the Software industry, placing it in the top 74.1%.
Is Avai Bio's Earnings Yield (Joel Greenblatt) % too high?
Avai Bio's current Earnings Yield (Joel Greenblatt) % is -1.91%. Based on the distribution chart, Avai Bio ranks #2151 out of 2902 companies in the Software industry, which is below the industry midpoint. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's Earnings Yield (Joel Greenblatt) % compare to IPM and RCT?
According to the Software industry distribution chart, Avai Bio ranks #2151 out of 2902 companies for Earnings Yield (Joel Greenblatt) %. This places Avai Bio in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 1.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Software company?
The median Earnings Yield (Joel Greenblatt) % among Software companies is 1.96, based on 2,902 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Avai Bio and its competitors. For the Software industry, the median Earnings Yield (Joel Greenblatt) % is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avai Bio's current Earnings Yield (Joel Greenblatt) % is -1.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current Earnings Yield (Joel Greenblatt) % of -1.91%. The current Earnings Yield (Joel Greenblatt) % is -1.91%. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Avai Bio (AVAI), the current Earnings Yield (Joel Greenblatt) % is -1.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score
Get the complete analysis for AVAI
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVAI has been successfully added to your 
